福元医药：获得克立硼罗原料药上市申请批准通知书

Core Viewpoint - The approval of the raw material drug Clobetasol by the National Medical Products Administration (NMPA) enhances the company's product line, although sales may face uncertainties due to policy and market factors [1] Group 1: Regulatory Approval - The company received the approval notice for Clobetasol raw material drug with registration number Y20240000682, valid until October 21, 2030 [1] - The technical review application for this raw material drug was accepted in July 2024, currently showing status "A" on the CDE raw and auxiliary materials registration information platform [1] Group 2: Product Indication - Clobetasol is indicated for local external treatment of mild to moderate atopic dermatitis in patients aged 2 years and older [1] Group 3: Market Considerations - The approval will enrich the company's product line, but drug sales are subject to uncertainties influenced by policies and market conditions [1]